Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies

被引:6
作者
Denys, Pierre
Corcos, Jacques
Everaert, Karel
Chartier-Kastler, Emmanuel
Fowler, Clare
Kalsi, Vinay
Nitti, Victor
Schulte-Baukloh, Heinrich
Schurch, Brigitte
机构
[1] Hop Raymond Poincare, F-92380 Garches, France
[2] McGill Univ, Jewish Gen Hosp, Dept Urol, Montreal, PQ H3T 1E2, Canada
[3] Ghent Univ Hosp, Dienst Urol, B-9000 Ghent, Belgium
[4] Grp Hosp Pitie Salpetriere, Dept Urol, F-75013 Paris, France
[5] UCL, Inst Neurol, Natl Hosp Neurol & Neurosurg, London, England
[6] NYU, Sch Med, Dept Urol, New York, NY 10003 USA
[7] St Hedwig Hosp, Dept Urol, Berlin, Germany
[8] Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland
关键词
botulinum toxin; global patient management; multidisciplinary; neurogenic urinary incontinence; neurological disease;
D O I
10.1185/030079906X104614
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with neurogenic bladder represent a small fraction of the total overactive bladder population. As a consequence, development of new therapies in this area has largely focused on idiopathic urinary incontinence. The absence of data for patients with neurological disease has far-reaching implications, affecting reimbursement and physicians' willingness to prescribe therapies, and limiting access of potential valuable treatments to patients whose lives are significantly impaired by inadequately managed bladder symptoms. Scope: The range of new therapies is increasing. Although many reviews of the overall safety, efficacy and mode of action of such treatments are available, there is limited information on how these treatments will best be used in clinical practice. We considered the current benefits and limitations of the various new licensed and unlicensed therapies and what role each would have in the future management of neurogenic urinary incontinence. Conclusions: A wide range of new treatments have been investigated for the management of overactive bladder; few, however, have been evaluated extensively in neurogenic urinary incontinence. Further studies are required to determine the optimal dosing regimes and formulations for individual sub-populations of neurogenic bladder patients and to determine the cost-effectiveness of these interventions. With the current experience available, two treatment algorithms for a subset of patients with neurological disease have also been proposed, which suggest at which stage of management and in which patients individual therapies for neurogenic urinary incontinence could be used.
引用
收藏
页码:851 / 860
页数:10
相关论文
共 66 条
[1]  
ANDERSON KE, 2005, INCONTINENCE, V2, P809
[2]   Oxybutynin and the overactive bladder [J].
Andersson, KE ;
Chapple, CR .
WORLD JOURNAL OF UROLOGY, 2001, 19 (05) :319-323
[3]   A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice [J].
Aoki, KR .
TOXICON, 2001, 39 (12) :1815-1820
[4]   Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity [J].
Apostolidis, A ;
Dasgupta, P ;
Fowler, CJ .
EUROPEAN UROLOGY, 2006, 49 (04) :644-650
[5]  
Appell RA, 2001, MAYO CLIN PROC, V76, P358
[6]   The therapeutic potential of cannabis [J].
Baker, D ;
Pryce, G ;
Giovannoni, G ;
Thompson, AJ .
LANCET NEUROLOGY, 2003, 2 (05) :291-298
[7]   Can higher doses of oxybutynin improve efficacy in neurogenic bladder? [J].
Bennett, N ;
O'Leary, M ;
Patel, AS ;
Xavier, M ;
Erickson, JR ;
Chancellor, MB .
JOURNAL OF UROLOGY, 2004, 171 (02) :749-751
[8]   Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm [J].
Bihari, K .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (03) :433-438
[9]   An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis [J].
Brady, CM ;
DasGupta, R ;
Dalton, C ;
Wiseman, OJ ;
Berkley, KJ ;
Fowler, CJ .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) :425-433
[10]   Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction [J].
Buyse, G ;
Verpoorten, C ;
Vereecken, R ;
Casaer, P .
JOURNAL OF UROLOGY, 1998, 160 (03) :1084-1087